Zhitong Finance App News, Kanghong Pharmaceutical (002773.SZ) issued an announcement. Recently, the company's subsidiary Chengdu Hongji Biotechnology Co., Ltd. (hereinafter referred to as “Hongji Biotech”) received the “Drug Clinical Trial Approval Notice” issued by the State Drug Administration, involving the drug: KH631 ophthalmic injection. Clinical trials for the treatment of diabetic macular edema (DME) will be conducted.

Zhitongcaijing · 6d ago
Zhitong Finance App News, Kanghong Pharmaceutical (002773.SZ) issued an announcement. Recently, the company's subsidiary Chengdu Hongji Biotechnology Co., Ltd. (hereinafter referred to as “Hongji Biotech”) received the “Drug Clinical Trial Approval Notice” issued by the State Drug Administration, involving the drug: KH631 ophthalmic injection. Clinical trials for the treatment of diabetic macular edema (DME) will be conducted.